Identifying risk factors for levels of per- and polyfluoroalkyl substances (PFAS) in the placenta in a high-risk pregnancy cohort in North Carolina

Jacqueline Bangma¹, Lauren A Eaves¹, Kirsi Oldenburg¹, Jessica L Reiner², Tracy Manuck^{3,4}, and Rebecca C Fry^{1,4,5}

SUPPLEMENTAL INFORMATION

Number of pages: 17

Number of files: 1

Number of tables: 9

Number of figures:1

File S1. File of calculated RL for each PFAS in each extracted placenta sample (See supplemental Excel file).

Figure S1. Correlogram demonstrating the associations between each of PFAS levels measured in the placenta for PFOS, PFHxS, PFHpS, and PFUnA. Blue circles indicate a positive correlation while red circles indicated a negative correlation. Intensity of color and size of the circle correspond to the magnitude of the association, in terms of absolute value of Spearman correlation coefficient. Blank indicates a non-significant association.

Table S1. Spearman correlation coefficients and associated p-values (in parentheses) of the correlations between PFAS measured in the placenta for PFOS, PFHxS, PFHpS, and PFUnA (ng/g).

Table S2. Comparisons of medians of PFAS levels (ng/g) by selected demographic variables. Tests of difference in medians evaluated by Wilcoxon test or Kruskal-Wallis test depending on if comparing two groups or over two groups, respectively, and p value of test listed.

Table S3. Comparisons of medians, IQR, maximum and minimum values of PFAS levels (ng/g) by hypertensive disorders of pregnancy (preeclampsia or gestational hypertension). p-value of test of difference in medians is listed.

Table S4. Comparisons of medians, IQR, maximum and minimum values of PFAS levels (ng/g) by fetal growth by the categories small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA). p-value of test of difference in medians is listed.

Table S5A. Beta values, standard error and associated p-values of crude linear regressions of PFAS level (ng/g) onto gestational age. Beta values represent predicted change in ng/g of PFAS with each additional 1 week of gestational age.

Table S5B. Beta values, standard error and associated p-values of adjusted, multivariate linear regressions of PFAS level (ng/g) onto gestational age. Beta values represent predicted change in ng/g of PFAS with each additional 1 week of gestational age, adjusted for maternal age, maternal smoking during pregnancy and maternal race.

Table S6. Crude (unadjusted) binomial regression models for relationship between gestational age and PFAS detection above RL for the seven PFAS detected below RL in approximately 50% or more of samples. Beta estimate represent the change in probability of PFAS being detected over the LOD with each 1 week increase in gestational age.

Table S7. Beta values, standard error and associated p-values of crude linear regressions of PFAS level (ng/g) onto delivery date. Beta values represent predicted change in ng/g of PFAS with each subsequent year of delivery (range 2015-2017). 2018 delivery dates (n=2) were removed from the analysis due to low sample size.

Table S8. NIST Standard Reference Material (SRM) 1947 certificate of analysis values compared to values obtained from methods employed in this study.

MATERIALS AND METHODS

2.2 Placenta PFAS quantification

Chemicals

Standard mixtures PFAC-MXC, HFPO-DA, and 6:2FTS from Wellington labs were combined to create calibration solutions. Combined, the solution contained a total of 22 PFAS as follows: (1) perfluorobutyric acid (PFBA), (2) per- fluoropentanoic acid (PFPeA), (3) perfluorohexanoic acid (PFHxA), (4) perfluoroheptanoic acid (PFHpA), (5) Perfluorooctanic acid (PFOA), (6) perfluorononanoic acid (PFNA), (7) perfluorodecanoic acid (PFDA), (8) perfluoroundecanoic acid (PFUdA), (9) perfluorodecanoic acid (PFDoA), (10) perfluorotridecanoic acid (PFTrDA), (11) perfluorobutanesulfonic acid (PFTeDA), (12) Perfluorohexadecanoic acid (PFHxDA), (13) perfluorobutanesulfonic acid (PFBS), (14) perfluoroheptanesulfonic acid (PFPeS), (15) perfluorodecanesulfonic acid (PFNX), (16) Perfluorononanesulfonic acid (PFNS), (17) perfluorodecanesulfonic acid (PFDS), (20) perfluorododecancesulfonic acid (PFDoS), (21) 1H, 1H, 2H, 2H-perfluorooctane sulfonic acid (6:2 FTS), and (22) 2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoroppoxy)propanoic acid (HFPO-DA also known as GenX).

Sample Preparation

All internal standards (IS) were purchased from Cambridge Isotope Laboratories (Andover, MA), RTI International (Research Triangle Park, NC), and Wellington Laboratories (Guelph, Ontario), in order to create an IS mixture that was comprised of a total of 15 isotopically labeled PFAS. The mixture is as follows: [13C4]PFBA,

[13C5]PFPeA, [13C5]PFHxA, [13C4]PFHpA, [13C8]PFOA, [13C9]PFNA, [13C6]PFDA, [13C7]PFUdA, [13C]PFDoA, [13C2]PFTeDA, [13C3]PFBS, [13C3]PFHxS, [13C8]PFOS, [13C2]6:2FTS, and [13C3]HFPO-DA.

For each blank, calibrant, and NIST Standard Reference Material (SRM) 1947 Lake Michigan Fish Tissue (used as control), approximately 1.0 g of sample was gravimetrically added to a 50 mL Falcon tube. A minimum of three blanks were included in the method. Each blank subsisted of approximately 1.0 g of de-ionized water. For the placental tissues, after trimming to approximately 1.0 g, excess blood was removed using methanol-rinsed foil. The sample was then re-weighed in the 50 mL falcon tube and the final weight recorded prior to extraction. The internal standard solution (approximately 200 μ L) was then added to each placenta, blank, and calibrant. Samples were vortexed and left to equilibrate for 1.5 h. A solution of 0.01 mol/L KOH (2.5 mL) in methanol was added, and the samples were sonicated for 30 min. The samples were then centrifuged for 5 min at 2500 rpm. The supernatant was removed and transferred to a clean glass culture tube. The addition of 0.01 mol/L KOH methanol and sonication was repeated. The combined supernatant was then evaporated under nitrogen at 35° C, resulting in a final volume of 2 mL using the TurboVap LV (Biotage, Uppsala, Sweden).

Each sample was further cleaned by being loaded into Supelco Supelclean ENVI-Carb SPE columns (3 mL, 250 mg, 120 to 400 mesh; Bellefonte, PA) and eluted with 2.5 ml methanol twice. The SPE cleaned fractions were evaporated at 48 KPa and 35 °C to 1 mL and the extracts were transferred to autosampler vials for analysis. Individual autosampler vials were analyzed using a liquid chromatograph coupled with a tandem mass spectrometer (LC-MS/MS). Three aliquots of SRM (1 mL each) were analyzed

S4

alongside samples and used as controls for this investigation. Values on the Certificate of Analysis were compared to PFAS measurements to assess the accuracy of the method.

LC-MS/MS data acquisition

Samples were analyzed using an Agilent 1100 High Performance Liquid Chromatography system (HPLC; Santa Clara, CA) coupled to an Applied Biosystems API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) with electrospray ionization in negative mode. Samples (5 μ L) were injected onto a Kinetex 2.6 μ PFP analytical column, (50 mm x 3 mm). The solvent gradient flow started at 25% 20 mmol ammonium acetate (volume fraction) in methanol and 75% 20 mmol ammonium acetate (volume fraction) in water (flow rate 150 μ L/min). Gradient flow increased to 28.5% methanol by 4.20 min, and further increased to 55% methanol by 15 min which held for 5 min. Methanol continued to increase to 62.5 % by 22 min and then a slow ramp to 87.5% methanol occurred by 52 min. The flow was then increased to 25% methanol at 55 min and held for 5 min. Following, the flow decreased to 25% methanol by 60.5 min and held until 70 min. Two multiple reaction monitoring (MRM) transitions for each PFAS were monitored to ensure no interferences. One MRM was employed for quantitation and the other transition was used for confirmation.¹

Quantification

Each PFAS was quantitated using a linear equation of the calibration curve when compared to internal standards of similar compounds. Using an established gravimetric method, the reporting limit (RL) is calculated in two ways: (1) using the lowest

S5

detectable calibrant divided by the mass of extracted sample or (2) taking the average amount of compound detected in the blanks divided by the mass of extracted sample. To be conservative, from the two methods of calculating the RL, the RL that was the highest for that PFAS and sample was designated as the respective RL for PFAS in that sample (**Supplemental File S1**).^{2,3} The concentrations determined include isomers within applicable PFAS. PFAS were included in further statistical analysis if approximately 50% or more of the samples were detected above the RL.⁴ Values on the Certificate of Analysis for SRM 1947 were compared to PFAS measurements to assess the accuracy of the method (**Supplemental Table S8**).

RESULTS

Comparison to National Vital Statistics Birth Data 2016 and 2017

In order to assess the representativeness of the present study cohort to pregnant women in the general US population, we compared demographic distributions in this cohort to National Vital Statistics Birth Data Report for 2017 (which includes data on 2016 as well).⁵ In 2016, the total percentage of women reporting smoking in pregnancy was 7.2%, in 2017, it was 6.9%. In this cohort 7.4% of women reported smoking, indicating that the distribution of smokers was similar to the US population. The mean age of mother at first birth in the total population was 26.8 in 2017 and 26.6 in 2016, in our study the mean age in 31.0, indicating that our cohort is slightly older than average, however the age of mother at first birth is rising.⁵ As in the present study population, in the general population, the largest percentage of births are paid by either private insurance (49.1%, 2017) or Medicaid (43%, 2017). In our study, private insurance and Medicaid were payment options for 53.9% and 38.5%, respectively, which is not

substantially different than the general population. The current study population is 37.% White non-Hispanic, 26.8% White, Hispanic, 33% non-Hispanic Black and 2.7% listed their race as "Other." The racial demographics of women who gave birth in 2017 vary slightly from this distribution with 51.68% of birth being to White mothers, 14.54% to non-Hispanic Black mothers, 23.3% to Hispanic mothers. The largest difference, as expected for a cohort of high risk of spontaneous preterm birth women, is in the gestational age at delivery, with extremely preterm births comprising 36.4%, later preterm births 9.9% and term 53.7% of the current cohort. Nationally, however, 90.07% of births in 2017 were term births. In sum, while this cohort is high-risk for spontaneous preterm birth and thus differ from the general population with regard to gestational age at delivery, for a number of key demographics (racial demographics, maternal age, insurance type and percentage of smokers) are not substantially different from pregnant women in the general U.S population.



Figure S1. Correlogram demonstrating the associations between each of the PFAS levels measured in the placenta for PFOS, PFHxS, PFHpS, and PFUnA. Blue circles indicate a positive correlation while red circles indicated a negative correlation. Intensity of color and size of the circle correspond to the magnitude of the association, in terms of absolute value of Spearman correlation coefficient. Blank indicates a non-significant association.

Table S1: Spearman correlation coefficients and associated p-values (in parentheses) of the correlations between PFAS measured in the placenta for PFOS, PFHxS, PFHpS, and PFUnA (ng/g).

PFAS	PFHxS	PFOS	PFHpS	PFUnA
PFHxS	1	0.425 (1.097 x10 ⁻⁶)	0.532 (2.907 x10 ⁻¹⁰)	0.037 (0.688)
PFOS	0.425 (1.097 x10 ⁻⁶)	1	0.493 (7.990 x10 ⁻⁹)	0.477 (2.786 x10 ⁻⁸)
PFHpS	0.532 (2.907 x10 ⁻¹⁰)	0.493 (7.990 x10 ⁻⁹)	1	0.192 (0.034)
PFUnA	0.037 (0.688)	0.477 (2.786 x10 ⁻⁸)	0.192 (0.034)	1

Table S2: Comparisons of medians of PFAS levels (ng/g) by selected demographic variables. Tests of difference in medians evaluated by Wilcoxon test or Kruskal-Wallis test depending on if comparing two groups or over two groups, respectively, and p value of test listed.

Image: bord in the strain of the s		Ν	PFHxS					PFOS					PFHpS					PFUnA				
Image: Problem intermation of the constraint of the constrain			Median	IQR	P-value	Min	Max	Median	IQR	Р-	Min	Max	Median	IQR	Р-	Min	Max	Median	IQR	P-value	Min	Max
Include Include 0.067 0.115 0.017 0.446 0.480 0.525 0.001 4.87 0.009 0.010 0.004 0.003 0.027 0.032 0.002 0.020 0.240 Bace & Hispanic Ethnicity White inspanic Non-Hispanic Hack Non-Hispanic Black Non-Hispanic Black Non-Hispanic Black 42 30 0.017 0.130 0.017 0.446 0.454 0.500 0.006 1.42 0.001 0.012 0.003 0.003 0.019 0.022 0.016 0.106 0.010 0.012 0.004 0.028 0.017 0.036 0.017 0.426 0.522 0.12 0.009 0.0008 0.005 0.005 0.014 0.028 0.011 0.016 0.010 0.011 0.011 0.014 0.028 0.011<		100	0.077	0.115		0.015	0.446	0.400	0.595	value	0.001	107	0.000	0.010	value	0.004	0.062	0.027	0.000		0.000	0.040
Race & Hispanic Ethnicity White non-Hispanic 30 Non-His		122	0.067	0.115		0.017	0.446	0.480	0.525		0.001	4.87	0.009	0.010		0.004	0.063	0.027	0.032		0.002	0.240
Race & Hispanic 0.16 0.16 0.16 0.16 0.16 0.17 0.17 0.130 0.017 0.446 0.500 0.0129 4.27 0.010 0.012 0.004 0.028 0.049 0.028 0.047 0.046 0.446 0.626 0.552 0.129 4.87 0.000 0.001 0.012 0.004 0.028 0.049 0.028 0.047 0.046 0.118 0.210 0.017 0.217 <					0.1.6					0.1.6					0.07					0.04		
Libricity White non-Hispanic Non-Hispanic Non-Hispanic Non-Hispanic Non-Hispanic Other 42 37 0.117 0.130 0.002 0.017 0.427 0.446 0.426 0.552 0.52 0.006 0.122 0.010 0.012 0.005 0.004 0.005 0.013 0.005 0.019 0.005 0.019 0.005 0.019 0.0047 0.020 0.043 0.018 0.240 0.017 0.242 0.226 0.322 0.122 0.010 0.011 0.012 0.004 0.028 0.017 0.056 0.018 0.240 0.017 0.242 0.240 0.240 0.013 0.010 0.011 0.013 0.004 0.028 0.017 0.056 0.018 0.012 0.001 0.011 0.013 0.014 0.015 0.014 0.020 0.014 0.012 0.011 0.014 0.013 0.011 0.014 0.013 0.011 0.014 0.013 0.011 0.013 0.014 0.011 0.013 0.011 0.014 0.013 0.011 0.013 0.013 0.011 0.013 0.013 0.011 0.013 0.014 0.013 0.013	Race & Hispanic				0.16					0.16					0.37					<0.01		
White non-Hispanic 42 0.117 0.130 0.017 0.446 0.500 0.000 1.42 0.010 0.012 0.004 0.028 0.019 0.029 0.016 0.019 0.029 0.014 0.029 0.014 0.029 0.014 0.029 0.014 0.029 0.0043 0.028 0.017 0.029 0.016 0.017 0.217 0.240 Non-Hispanic Black 37 0.047 0.165 0.043 0.228 0.047 0.063 0.041 0.012 0.004 0.028 0.044 0.042 0.016 0.017 0.217 Other 3 0.047 0.163 0.040 0.377 0.569 0.503 0.164 1.91 0.010 0.002 0.004 0.037 0.017 0.217 0.217 0.010 0.002 0.004 0.033 0.032 0.001 0.017 0.017 0.217 0.217 0.217 0.010 0.002 0.028 0.027 0.031 0.002 0.017	Ethnicity										0.000		0.040									
White Hispanic 30 0.069 0.102 0.017 0.427 0.625 0.522 0.129 4.87 0.009 0.008 0.005 0.043 0.056 0.018 0.0217 0.035 0.017 0.322 0.017 0.322 0.017 0.321 0.017 0.325 0.127 0.325 0.128 0.011 0.011 0.011 0.011 0.011 0.011 0.012 0.017 0.017 0.127 0.155 0.127 0.155 0.128 0.011 0.011 0.011 0.011 0.011 0.012 0.023 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.013 0.011 0.013 0.011 0.013 0.011 0.013 0.011 0.014 0.013 0.011 0.013 0.012 0.013 0.013 0.013 0.013 0.013 0.013 0.013	White non-Hispa	nic 42	0.117	0.130		0.017	0.446	0.454	0.500		0.006	1.42	0.010	0.012		0.004	0.028	0.019	0.020		0.016	0.100
Non-Hispanic Black 37 Other 0.052 0.047 0.017 0.165 0.017 0.048 0.432 0.208 0.432 0.552 0.487 0.495 0.001 1.71 0.881 0.006 0.013 0.010 0.004 0.025 0.04 0.042 0.017 0.217 Maternal Smoking No Ves 9 No 112 0.166 0.03 0.047 0.569 0.532 0.164 1.91 0.010 0.004 0.043 0.033 0.039 0.014 0.043 0.039 0.032 0.031 0.045 0.111 0.045 0.117 0.217 Missing 1 0.063 0.181 0.017 0.446 0.569 0.502 0.014 1.91 0.002 0.004 0.043 0.039 0.032 0.031 0.002 0.217 0.217 Missing 1 0.068 0.117 0.446 0.476 0.516 0.004 4.87 0.001 0.011 0.002 0.023 0.033 0.033 0.033 0.033 0.003 0.016 0.177	White Hispa	nic 30	0.069	0.102		0.017	0.427	0.626	0.552		0.129	4.87	0.009	0.008		0.005	0.063	0.047	0.056		0.018	0.240
Other 3 0.047 0.165 0.043 0.208 0.552 0.386 0.495 0.881 0.013 0.0030 0.011 0.014 0.081 0.111 0.045 0.156 Maternal Smoking Nissing 9 0.124 0.116 0.040 0.377 0.569 0.502 0.114 1.91 0.010 0.002 0.004 0.043 0.039 0.032 0.031 0.027 0.031 0.017 0.216 0.004 0.011 0.004 0.063 0.027 0.031 0.012 0.217 0.217 0.217 0.217 0.216 0.016 0.111 0.004 0.013 0.004 0.013 0.027 0.033 0.016 0.117	Non-Hispanic Bla	ack 37	0.052	0.079		0.017	0.362	0.432	0.407		0.001	1.71	0.006	0.010		0.004	0.025	0.04	0.042		0.017	0.217
Maternal Smoking Yes 9 No 0.12 10 0.03 0.063 0.040 0.181 0.037 0.017 0.569 0.459 0.502 0.502 0.164 0.001 1.91 0.009 0.010 0.002 0.001 0.004 0.004 0.043 0.063 0.039 0.027 0.032 0.031 0.017 0.217 0.217 Missing Missing 1 0.068 0.117 0.446 0.476 0.515 0.004 0.011 0.013 0.027 0.031 0.017 0.217 Maternal Smoking Missing 1 0.068 0.117 0.446 0.446 0.515 0.004 0.011 0.004 0.063 0.027 0.031 0.016 0.117 Maternal pre-pregnancy BMI 0.0067 0.016 0.213 0.627 0.648 0.116 0.978 0.016 0.011 0.004 0.063 0.020 0.003 0.016 0.177 Maternal pre-pregnancy BMI 0.006 0.089 0.018 0.213 0.627 0.668 0.016 0.978 0.015 0.014 0.004 0.025 0.024 0.025 <	Otl	her 3	0.047	0.165		0.043	0.208	0.552	0.386		0.495	0.881	0.013	0.0030		0.011	0.014	0.081	0.111		0.045	0.156
Maternal Smoking No Ves 9 (124) 0.124 (0.63) 0.114 (0.181) 0.040 (0.181) 0.037 (0.446) 0.659 (0.59) 0.502 0.164 (0.601) 1.91 (0.009) 0.010 (0.009) 0.004 (0.009) 0.033 (0.004) 0.033 (0.027) 0.031 (0.033) 0.017 (0.031) 0.017 (0.009) 0.010 (0.009) 0.010 (0.009) 0.010 (0.009) 0.010 (0.004) 0.033 (0.004) 0.031 (0.027) 0.031 0.017 (0.009) 0.217 (0.009) Child's Gender Male Female 54 (0.067) 0.016 0.17 0.446 0.476 0.515 0.064 0.011 0.010 0.004 0.063 0.020 0.003 0.016 0.177 Maternal pre-pregnancy BMI C 0.017 0.446 0.476 0.515 0.004 0.011 0.004 0.063 0.020 0.003 0.016 0.177 Maternal pre-pregnancy BMI C 0.016 0.213 0.627 0.668 0.166 0.978 0.014 0.014 0.004 0.025 0.024 0.025 0.017 0.240 Stati																						
Yes 9 0.124 0.116 0.040 0.377 0.569 0.503 0.164 1.91 0.010 0.002 0.004 0.043 0.039 0.032 0.031 0.032 0.017 0.217 0.217 0.217 0.217 0.010 0.002 0.004 0.003 0.039 0.032 0.031 0.002 0.240 Missing 1 0.068 0.117 0.446 0.459 0.502 0.001 4.87 0.009 0.010 0.004 0.063 0.027 0.031 0.002 0.240 Child's Gender 0.89 0.017 0.446 0.476 0.515 0.004 0.91 0.014 0.063 0.027 0.003 0.016 0.177 Missing 1 0.016 0.117 0.476 0.476 0.515 0.004 0.91 0.016 0.025 0.003 0.003 0.002 0.024 0.025 0.003 0.002 0.240 0.025 0.003 0.00	Maternal Smoking				0.03					0.12					0.28					0.90		
No 112 0.063 0.181 0.017 0.446 0.459 0.502 0.001 4.87 0.009 0.010 0.004 0.063 0.027 0.031 0.002 0.240 Missing 1 0.068 0.117 0.446 0.459 0.502 0.001 4.87 0.009 0.010 0.004 0.063 0.027 0.031 0.002 0.240 Child's Gender Emale 54 0.068 0.117 0.017 0.446 0.476 0.515 0.004 0.011 0.004 0.063 0.020 0.003 0.016 0.177 Mate 67 0.067 0.116 0.017 0.377 0.446 0.546 0.005 1.91 0.009 0.011 0.004 0.063 0.020 0.003 0.016 0.177 Maternal pre-pregnancy BMI 0.006 0.089 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.	,	Yes 9	0.124	0.116		0.040	0.377	0.569	0.503		0.164	1.91	0.010	0.002		0.004	0.043	0.039	0.032		0.017	0.217
Missing 1 Image: Search of the search o		No 112	0.063	0.181		0.017	0.446	0.459	0.502		0.001	4.87	0.009	0.010		0.004	0.063	0.027	0.031		0.002	0.240
Child's Gender 0.068 0.017 0.446 0.476 0.515 0.004 4.87 0.001 0.011 0.004 0.063 0.020 0.003 0.016 0.177 Male 67 0.067 0.116 0.017 0.377 0.446 0.546 0.004 4.87 0.001 0.011 0.004 0.065 0.003 0.003 0.016 0.177 0.240 Maternal pre-pregnancy BM1 0.006 0.089 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 Maternal pre-pregnancy BM1 0.006 0.089 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 BM1 0.005 0.017 0.363 0.506 0.602 0.001 1.18 0.010 0.004 0.028 0.024 0.025 0.017 0.156 BM1 0.015 0.139	Miss	ing 1																				
Child's Gender 0.89 0.66 0.66 0.001 0.011 0.004 0.063 0.020 0.003 0.016 0.117 Male 67 0.067 0.116 0.017 0.37 0.466 0.515 0.004 4.87 0.001 0.011 0.004 0.063 0.020 0.003 0.016 0.117 0.016 0.117 0.016 0.117 0.016 0.117 0.016 0.117 0.016 0.117 0.016 0.117 0.002 0.003 0.016 0.117 0.002 0.020 0.003 0.016 0.117 0.002 0.024 0.025 0.003 0.002 0.240 0.002 0.240 0.002 0.003 0.016 0.177 0.002 0.017 0.165 0.25 0.25 0.017 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 0.240 0.240 0.017 0.240 0.240 0.024 0.025 0.017 0.217	11133	<u>6</u> 1																				
General pre-pregnancy BMI C.0.05 0.017 0.446 0.476 0.515 0.004 4.87 0.001 0.011 0.004 0.063 0.020 0.003 0.016 0.117 0.016 0.117 0.017 0.446 0.476 0.515 0.005 1.91 0.001 0.011 0.004 0.063 0.020 0.003 0.016 0.117 0.016 0.117 0.001 0.016 0.011 0.004 0.055 0.003 0.003 0.016 0.117 Maternal pre-pregnancy BMI 0.35 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 18.5 6 0.006 0.089 0.0165 0.256 0.403 0.404 0.006 1.82 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 25-<30 30 0.075 0.139 0.017 0.363 0.506<	Child's Gender				0.89					0.66					0.32					0.81		
Male 67 0.067 0.116 0.017 0.377 0.490 0.546 0.005 1.91 0.009 0.008 0.004 0.055 0.025 0.037 0.003 0.002 0.240 Maternal pre-pregnancy BMI 0.056 0.0067 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.116 Maternal pre-pregnancy BMI 0.035 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 25 24 0.050 0.078 0.0165 0.256 0.403 0.404 0.006 1.82 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 18.5 6 0.005 0.017 0.363 0.506 0.602 0.001 1.18 0.010 0.009 0.004 0.025 0.024 0.025 0.017 0.240 0.240 0.213 0.017	Fem	ale 54	0.068	0.117	0.09	0.017	0.446	0.476	0.515	0.00	0.004	487	0.001	0.011	0.52	0.004	0.063	0.020	0.003	0.01	0.016	0.177
Maternal pre-pregnancy BMI 0.005 0.017 0.037 0.037 0.037 0.034 0.005 0.00	M	ale 67	0.067	0.116		0.017	0.377	0.490	0.546		0.0005	1.07	0.009	0.008		0.004	0.055	0.020	0.003		0.002	0.240
Maternal pre-pregnancy BMI 0.35 0.25 0.006 0.098 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 18.5 < 6 0.006 0.098 0.0165 0.256 0.403 0.404 0.006 1.82 0.005 0.007 0.004 0.028 0.024 0.025 0.017 0.156 18.5 < 25 24 0.050 0.078 0.0165 0.256 0.403 0.404 0.006 1.82 0.005 0.007 0.004 0.028 0.024 0.025 0.017 0.156 18.5 < 40 0.075 0.139 0.017 0.363 0.506 0.602 0.001 1.18 0.010 0.004 0.027 0.038 0.028 0.017 0.217 30 + 62 0.073 0.105 0.017 0.446 0.495 0.495 0.004 4.87 0.010 0.011 0.004 0.063 0.020	Miss	ing 1	0.007	0.110		0.017	0.577	0.490	0.540		0.0005	1.91	0.009	0.008		0.004	0.055	0.037	0.005		0.002	0.240
Maternal pre-pregnancy BMI 0.35 0.25 0.60 0.80 18.5 6 0.006 0.089 0.018 0.213 0.627 0.668 0.166 0.978 0.015 0.014 0.004 0.028 0.024 0.025 0.017 0.156 18.5 25 24 0.050 0.078 0.0165 0.256 0.403 0.404 0.006 1.82 0.005 0.007 0.004 0.028 0.024 0.025 0.017 0.156 25 30 0.075 0.139 0.017 0.363 0.506 0.602 0.001 1.18 0.010 0.009 0.004 0.027 0.038 0.028 0.017 0.217 30+ 62 0.073 0.105 0.017 0.446 0.495 0.495 0.004 4.87 0.010 0.011 0.004 0.023 0.020 0.032 0.002 0.017 0.217 Missing 0 0.017 0.446 0.495 0.495<	11185	ing i																				
Matching prepregnancy 0.55 0.05 0.05 0.00 0.00 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.001 0.017 0.156 BMI <18.5	Matarnal nra nragnanc	v			0.35					0.25					0.60					0.80		
<18.5	DMI	y			0.55					0.25					0.00					0.80		
18.5- 25 24 0.050 0.078 0.016 0.215 0.027 0.008 0.116 0.978 0.013 0.014 0.004 0.028 0.024 0.023 0.024 0.023 0.017 0.116 0.116 18.5- 25 24 0.050 0.078 0.0165 0.256 0.403 0.404 0.006 1.82 0.005 0.007 0.004 0.055 0.020 0.054 0.017 0.240 25-<30		95 6	0.006	0.080		0.018	0.212	0.627	0.669		0.166	0.078	0.015	0.014		0.004	0.028	0.024	0.025		0.017	0.156
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	~1 195 -	0. 5 0	0.000	0.089		0.0165	0.213	0.027	0.008		0.100	1.97	0.015	0.014		0.004	0.028	0.024	0.023		0.017	0.130
25-30 30 0.075 0.139 0.017 0.363 0.506 0.602 0.001 1.18 0.010 0.009 0.004 0.027 0.038 0.028 0.017 0.217 30+ 62 0.073 0.105 0.017 0.446 0.495 0.495 0.004 4.87 0.010 0.011 0.004 0.027 0.038 0.028 0.002 0.177 Missing 0 0 0.010 0.011 0.004 0.063 0.020 0.032 0.002 0.177	18.3-	~23 24	0.050	0.078		0.0105	0.230	0.403	0.404		0.000	1.62	0.003	0.007		0.004	0.055	0.020	0.034		0.017	0.240
30+ 62 0.073 0.105 0.017 0.446 0.495 0.495 0.004 4.87 0.010 0.011 0.004 0.063 0.020 0.032 0.002 0.177	25-<	< 30 30	0.075	0.139		0.017	0.363	0.506	0.602		0.001	1.18	0.010	0.009		0.004	0.027	0.038	0.028		0.017	0.217
Missing ()	3	30 + 62	0.073	0.105		0.017	0.446	0.495	0.495		0.004	4.87	0.010	0.011		0.004	0.063	0.020	0.032		0.002	0.177
WIISSING 0	Miss	ing 0																				
		0																				
Maternal age 0.82 0.35 0.09 0.21	Maternal age				0.82					0.35					0.09					0.21		
<20 1 0.064 0 0.064 0.064 0.166 0 0.166 0.166 0.004 0 0.004 0.004 0.017 0 0.017 0.017	<	< 20 1	0.064	0		0.064	0.064	0.166	0		0.166	0.166	0.004	0		0.004	0.004	0.017	0		0.017	0.017
20-<35 77 0.067 0.102 0.017 0.446 0.484 0.486 0.001 1.91 0.009 0.009 0.004 0.043 0.034 0.028 0.002 0.134	20-<	<35 77	0.067	0.102		0.017	0.446	0.484	0.486		0.001	1.91	0.009	0.009		0.004	0.043	0.034	0.028		0.002	0.134
35+ 44 0.068 0.116 0.017 0.427 0.485 0.569 0.004 4.87 0.011 0.011 0.004 0.063 0.022 0.057 0.016 0.240	3	35 + 44	0.068	0.116		0.017	0.427	0.485	0.569		0.004	4.87	0.011	0.011		0.004	0.063	0.022	0.057		0.016	0.240

Missing	0																				
Maternal medical				0.19					0.60					0.11					0.29		
Private insurance Private insurance Medicare/Medicaid Self-pay Missing	56 40 8 18	0.105 0.051 0.067	0.129 0.100 0.026		0.017 0.017 0.024	0.363 0.446 0.241	0.501 0.362 0.649	0.529 0.486 0.504		0.001 0.006 0.192	1.82 1.91 1.26	0.010 0.005 0.010	0.011 0.009 0.008		0.004 0.004 0.005	0.028 0.043 0.019	0.037 0.020 0.047	0.034 0.025 0.051		0.016 0.002 0.018	0.156 0.240 0.094
Manaka	10			0.42					0.40					0.65					0.70		
Maternal Education Less than high school Completed high school More than high school Declined/missing	13 42 34 33	0.071 0.074 0.090	0.058 0.155 0.092	0.43	0.018 0.017 0.017	0.142 0.446 0.363	0.608 0.556 0.432	0.794 0.581 0.553	0.40	0.141 0.006 0.0005	1.72 4.87 1.18	0.009 0.010 0.011	0.065 0.014 0.010	0.65	0.005 0.004 0.004	0.018 0.063 0.025	0.025 0.020 0.020	0.035 0.028 0.029	0.70	0.017 0.016 0.0170	0.240 0.217 0.156
Marital status Married Not married Missing	81 33 8	0.072 0.065	0.119 0.073	0.73	0.017 0.017	0.446 0.266	0.475 0.490	0.557 0.469	1.00	0.001 0.006	4.87 1.71	0.009 0.010	0.009 0.011	0.24	0.004 0.004	0.063 0.025	0.036 0.020	0.034 0.024	0.59	0.016 0.002	0.240 0.217
Delivered Preterm Extremely preterm (<34	45	0.053	0.101	0.65	0.017	0.361	0.490	0.385	0.57	0.006	1.71	0.005	0.007	0.16	0.004	0.028	0.036	0.030	0.31	0.002	0.240
Preterm (34-<37 weeks) Term (37+weeks)	12 65	0.085 0.073	0.098 0.104		0.017 0.017	0.332 0.446	0.538 0.432	0.465 0.563		0.151 0.001	1.11 4.87	0.012 0.010	0.011 0.011		0.004 0.004	0.025 0.063	0.020 0.020	0.022 0.036		0.016 0.017	0.052 0.217

P-values obtained from Wilcoxon test for sociodemographic variables, which have more than two groups. Values below the RL have been imputed as half the RL.

Table S3. Comparisons of medians, IQR, maximum and minimum values of PFAS levels (ng/g) by hypertensive disorders of pregnancy (preeclampsia or gestational hypertension). p-value of test of difference in medians is listed.

					PFHxS					PFOS					PFHpS					PFUnA		
		Ν	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value
		122	0.067	0.115	0.017	0.446		0.480	0.525	0.001	4.87		0.009	0.010	0.004	0.063		0.027	0.032	0.002	0.240	
Hypertensive disorders of							0.47					0.11					0.22					0.09
pregnancy	No	108	0.066	0.114	0.017	0.446		0.459	0.497	0.001	4.87		0.009	0.001	0.004	0.063		0.020	0.030	0.002	0.240	
	Yes	14	0.112	0.118	0.017	0.377		0.765	0.583	0.151	1.91		0.011	0.015	0.005	0.043		0.044	0.037	0.018	0.217	
P-values obtained Values below the ¹ Defined as eithe	d from W e RL have er gestatio	ilcoxon e been in onal hyp	test. puted as half ertension or p	the RL.																		

Table S4. Comparisons of medians, IQR, maximum and minimum values of PFAS levels (ng/g) by fetal growth by the categories small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA). p-value of test of difference in medians is listed.

				PFHxS					PFOS					PFHpS					PFUnA		
	Ν	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value	Median	IQR	Min	Max	p-value
	122	0.067	0.115	0.017	0.446		0.480	0.525	0.001	4.87		0.009	0.0010	0.004	0.063		0.027	0.032	0.002	0.240	
Fetal growth						0.98					0.82					0.87					0.37
SGA	9	0.072	0.142	0.017	0.446		0.381	0.525	0.242	1.82		0.009	0.006	0.005	0.025		0.042	0.052	0.002	0.112	
AGA	92	0.067	0.111	0.017	0.427		0.480	0.501	0.0005	4.87		0.01	0.011	0.004	0.063		0.020	0.028	0.016	0.240	
LGA	12	0.060	0.081	0.018	0.363		0.589	0.433	0.006	1.26		0.009	0.014	0.005	0.025		0.044	0.036	0.018	0.094	
P-values obtained from Kr	uskal-W	Vallis test.																			

Values below the RL have been imputed as half the RL.

Table S5A. Beta values, standard error and associated p-values of crude linear regressions of PFAS level (ng/g) onto gestational age. Beta values represent predicted change in ng/g of PFAS with each additional 1 week of gestational age.

	Beta value	Standard error	P-value
PFOS	0.000	0.009	0.98
PFHxS	0.002	0.002	0.18
PFUnA	0.000	0.001	0.94
PFHpS	0.002	0.000	0.20

Table S5B. Beta values, standard error and associated p-values of adjusted, multivariate linear regressions of PFAS level (ng/g) onto gestational age. Beta values represent predicted change in ng/g of PFAS with each additional 1 week of gestational age, adjusted for maternal age, maternal smoking during pregnancy and maternal race.

	Beta value	Standard error	P-value
PFOS	-0.005	0.009	0.56
PFHxS	0.002	0.002	0.22
PFUnA	-0.001	0.001	0.36
PFHpS	0.000	0.000	0.40

producinity of fifths being detected over the hold with each f week hiere											
	Beta value	Standard error	p-value								
PFOA	0.015	0.007	0.04								
PFNA	0.006	0.007	0.36								
PFDA	0.004	0.008	0.66								
PFTriA	-0.013	0.008	0.10								
PFPeS	0.007	0.008	0.38								
PFTA	-0.007	0.004	0.11								
PFHxA	-0.002	0.002	0.32								

Table S6: Crude (unadjusted) binomial regression models for relationship between gestational age and PFAS detection above RL for the seven PFAS detected below RL in approximately 50% or more of samples (ie. 0=below RL, 1=detected above RL). Beta value represents the change in probability of PFAS being detected over the LOD with each 1 week increase in gestational age.

Table S7: Beta values, standard error and associated p-values of crude linear regressions of PFAS level (ng/g) onto delivery date. Beta values represent predicted change in ng/g of PFAS with each subsequent year of delivery (range 2015-2017). 2018 delivery dates (n=2) were removed from the analysis due to low sample size.

	Beta value	Standard error	P-value
PFOS	-0.044	0.067	0.51
PFHxS	-0.024	0.011	0.04
PFUnA	-0.001	0.001	0.36
PFHpS	0.007	0.005	0.14

Table S8: NIST Standard Reference Material (SRM)) 1947 certificate of analysis	values compared to values obtained	from methods
employed in this study. Not provided (NP)			

	Mea	asured	Certificate of Analysis							
PFAS	Measured Mean (ng/g)	Measured 95% CI (lower bound- upper bound)	Reported Mean (ng/g)	Uncertainty	Reported 95% CI (lower bound- upper bound)					
PFOS	5.53	5.14-5.92	5.90	0.39	5.51-6.29					
PFNA	0.217	0.17-0.26	0.2	NP	NP					
PFDA	0.202	0.12-0.28	0.26	NP	NP					
PFUnA	0.263	0.23-0.29	0.28	NP	NP					
PFTriA	0.172	0.17-0.18	0.2	NP	NP					

REFERENCES

 Reiner, J. L.; Phinney, K. W.; Keller, J. M., Determination of perfluorinated compounds in human plasma and serum Standard Reference Materials using independent analytical methods. *Anal. Bioanal. Chem.* 2011, *401* (9), 2899-2907.
 Kurtz, A. E.; Reiner, J. L.; West, K. L.; Jensen, B. A., Perfluorinated Alkyl Acids in Hawaiian Cetaceans and Potential Biomarkers of Effect: Peroxisome Proliferator-Activated Receptor Alpha and Cytochrome P450 4A. *Environ. Sci. Technol.* 2019.
 Reiner, J. L.; O'Connell, S. G.; Moors, A. J.; Kucklick, J. R.; Becker, P. R.; Keller, J. M., Spatial and temporal trends of perfluorinated compounds in beluga whales (Delphinapterus leucas) from Alaska. *Environ. Sci. Technol.* 2011, *45* (19), 8129-8136.
 Starling AP; Engel SM; Richardson DB; Baird DD; Haug LS; Stuebe AM; Klungsøyr K; Harmon Q; Becher G; Thomsen C; Sabaredzovic A; Eggesbø M; Hoppin JA; Travlos GS; Wilson RE; Trogstad LI; Magnus P; MP, L., Perfluoroalkyl substances during pregnancy and validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort Study. *Am. J. Epidemiol.* 2014, *179* (7), 824-833.

5. Hamilton, B. E.; Osterman, M. J.; Driscoll, A. K.; Rossen, L. M., Births: Provisional data for 2017. 2018.